RD

Robert E. Davis

IT Intra-Cellular Therapies: 70 patents #3 of 40Top 8%
MI Mitokor: 19 patents #1 of 30Top 4%
AP Acadia Pharmaceuticals: 17 patents #6 of 83Top 8%
GE Geodynamics: 9 patents #13 of 54Top 25%
AP Arkansas Patents: 8 patents #1 of 4Top 25%
MI Migenix: 7 patents #2 of 34Top 6%
SI Snap-On Incorporated: 4 patents #114 of 458Top 25%
FC Federal Paper Board Co.: 4 patents #9 of 26Top 35%
RC R. E. Davis Chemical: 3 patents #1 of 2Top 50%
WC Warner-Lambert Company: 2 patents #646 of 1,610Top 45%
BA Ball: 2 patents #113 of 366Top 35%
IT Ideal Toy: 2 patents #6 of 23Top 30%
KC Kerr-Mcgee Chemical: 2 patents #33 of 115Top 30%
VI Vickers: 2 patents #29 of 188Top 20%
HO Honeywell: 1 patents #7,507 of 14,447Top 55%
HA Hanes: 1 patents #3 of 8Top 40%
RI Riverwood International: 1 patents #58 of 92Top 65%
RS R.R. Donnelly & Sons: 1 patents #2 of 9Top 25%
SL Sara Lee: 1 patents #108 of 246Top 45%
University of California: 1 patents #8,022 of 18,278Top 45%
UL United Laboratories: 1 patents #7 of 13Top 55%
UN Unknown: 1 patents #29,356 of 83,584Top 40%
EL Elekta Limited: 1 patents #61 of 144Top 45%
📍 San Diego, CA: #128 of 23,606 inventorsTop 1%
🗺 California: #758 of 386,348 inventorsTop 1%
Overall (All Time): #4,651 of 4,157,543Top 1%
172
Patents All Time

Issued Patents All Time

Showing 76–100 of 172 patents

Patent #TitleCo-InventorsDate
9745300 Organic compounds Sharon Mates, Peng Li, Lawrence P. Wennogle 2017-08-29
9708322 Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity Peng Li, Qiang Zhang, Lawrence P. Wennogle 2017-07-18
9630971 Free base crystals Takashi Abe, Graham Buckton, Mark Hooper, Peng Li, Hideaki Maruyama +4 more 2017-04-25
9566271 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2017-02-14
9469647 Salt crystals Peng Li, Lawrence P. Wennogle, Graham Buckton, Mark Hooper 2016-10-18
9428506 Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders Sharon Mates, Peng Li, Lawrence P. Wennogle, Kimberly VANOVER 2016-08-30
9371324 Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders Sharon Mates, Lawrence P. Wennogle, Peng Li, John Charles Tomesch, Qiang Zhang 2016-06-21
9211289 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2015-12-15
9117321 Method and apparatus to use remote and local control modes to acquire and visually present data Michel B. Alberry, Timothy G. Ruther, Anthony J. Cichy 2015-08-25
8993572 Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives Sharon Mates, Lawrence P. Wennogle, Peng Li, John Charles Tomesch, Qiang Zhang 2015-03-31
8935440 System and method for integrating devices for servicing a device-under-service Michel B. Alberry, Timothy G. Ruther, Anthony J. Cichy 2015-01-13
8921393 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2014-12-30
8618130 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldan 2013-12-31
8463953 System and method for integrating devices for servicing a device-under-service Michel B. Alberry, Timothy G. Ruther, Anthony J. Cichy 2013-06-11
8377959 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2013-02-19
8227487 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2012-07-24
8008323 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2011-08-30
7994193 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2011-08-09
7875632 Selective serotonin receptor inverse agonists as therapeutics for disease David M. Weiner, Mark R. Brann 2011-01-25
7863296 Selective serotonin receptor inverse agonists as therapeutics for disease David M. Weiner, Mark R. Brann, Norman Nash 2011-01-04
7820695 Selective serotonin receptor inverse agonists as therapeutics for disease David M. Weiner, Mark R. Brann 2010-10-26
7732462 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2010-06-08
7713995 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Norman Nash, Carl-Magnus A. Andersson, Allan K. Uldam 2010-05-11
7659285 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2010-02-09
7601740 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases David M. Weiner, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2009-10-13